Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers
- 8 March 2000
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 40 (3), 316-323
- https://doi.org/10.1177/00912700022008874
Abstract
This study was conducted to evaluate the potential pharmacokinetic interaction between fenofibrate and pravastatin. A total of 23 healthy adult volunteers received single‐dose 201 mg fenofibrate alon...Keywords
This publication has 15 references indexed in Scilit:
- Role of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (“Statins”) in Familial Combined HyperlipidemiaThe American Journal of Cardiology, 1998
- Micronised FenofibrateDrugs, 1997
- Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- Clinical Pharmacokinetics of PravastatinClinical Pharmacokinetics, 1994
- Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in manMetabolism, 1992
- Relative Lipophilicities, Solubilities, and Structure–Pharmacological Considerations of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors Pravastatin, Lovastatin, Mevastatin, and SimvastatinJournal of Pharmaceutical Sciences, 1991
- Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of CholesterolNew England Journal of Medicine, 1990
- Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.British Journal of Clinical Pharmacology, 1990
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988